Skip to main content

Advertisement

Log in

Overview of the management of differentiated thyroid cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Thyroid cancer is an uncommon tumor accounting for roughly 1% of all new malignancies. Differentiated (ie, papillary or follicular) thyroid carcinoma is usually asymptomatic, and frequently appears as a solitary thyroid nodule but few show cervical lymphadenopathy or metastasis to lung, bone, or liver. Fine needle aspiration (FNA) is recommended in the initial diagnostic test. Depending on the size of the lesion and other associated risk factors, most patients are treated with total or near total thyroidectomy. Postoperative radioiodine ablation is performed when tumor has a potential for recurrence. Recurrence rates and cancer-specific mortality is decreased by suppressing thyroid stimulating hormone (TSH). Long-term surveillance and follow-up with physical examination every 3 to 6 months for 2 years and then annually if patient remains cancer free. Whole body iodine scans are done every 12 months for follow-up until one negative scan (either withdrawal of thyroid hormone or rhodium complex [rh]-TSH). Thyroglobulin measurements (with antithyroglobulin antibodies) and ultrasound neck are suggested at 6 and 12 months and then annually if disease free.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med 1993, 328:553–559.

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29. Most recent data on thyroid cancer incidence,mortality. Compiled by American Cancer Society.

    PubMed  Google Scholar 

  3. Figge J JT, Gerasimov G: Thyroid cancer: a comprehensive guide to clinical mangement. Humana Press 1999, 85–116.

  4. Pacini F, Vorontsova T, Demidchik EP, et al.: Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997, 82:3563–3569.

    Article  PubMed  CAS  Google Scholar 

  5. Alsanea O, Wada N, Ain K, et al.: Is familial nonmedullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 2000, 128:1043–1050.

    Article  PubMed  CAS  Google Scholar 

  6. Sherman SI: Thyroid carcinoma. Lancet 2003, 361:501–511. Management of thyroid cancer including differentiated,medullary and anaplastic

    Article  PubMed  Google Scholar 

  7. Rosai J: Rosai and Ackerman’s Surgical Pathology. New York: Mosby, 2004.

    Google Scholar 

  8. Lee TI, Yang HJ, Lin SY, et al.: The accuracy of fine-needle aspiration biopsy and frozen section in patients with thyroid cancer. Thyroid 2002, 12:619–626. Comparison of FNAB and FNAC in diagnosing thyroid cancer in 1076 patients.

    Article  PubMed  Google Scholar 

  9. Dragoiescu C, Hoekstra OS, Kuik DJ, et al.: Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2003, 58:451–455.

    Article  CAS  Google Scholar 

  10. Singer PA, Cooper DS, Daniels GH, et al.: Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996, 156:2165–2172.

    Article  PubMed  CAS  Google Scholar 

  11. Netterville JL, Coleman SC, Smith JC, et al.: Management of substernal goiter. Laryngoscope 1998, 108:1611–1617.

    Article  PubMed  CAS  Google Scholar 

  12. Witte J, Goretzki PE, Dieken J, et al.: Importance of lymph node metastases in follicular thyroid cancer. World J Surg 2002, 26:1017–1022.

    Article  PubMed  Google Scholar 

  13. Voutilainen PE, Multanen MM, Leppaniemi AK, et al.: Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001, 11:953–957.

    Article  PubMed  CAS  Google Scholar 

  14. Freudenberg LS, Antoch G, Jentzen W, et al.: Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004. Comparison of PET /CT scan and radioiodine whole body scan in 12 patients with thyroid cancer.

  15. Tiepolt C, Beuthien-Baumann B, Hliscs R, et al.: 18F-FDG for the staging of patients with differentiated thyroid cancer: comparison of a dual-head coincidence gamma camera with dedicated PET. Ann Nucl Med 2000, 14:339–345.

    PubMed  CAS  Google Scholar 

  16. Mulcahy MM, Cohen JI, Anderson PE, et al.: Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of well-differentiated thyroid cancer. Laryngoscope 1998, 108:494–496.

    Article  PubMed  CAS  Google Scholar 

  17. Lumachi F, Borsato S, Tregnaghi A, et al.: Accuracy of fine-needle aspiration cytology and frozen-section examination in patients with thyroid cancer. Biomed Pharmacother 2004, 58:56–60.

    Article  PubMed  CAS  Google Scholar 

  18. American Association of Clinical Endocrinologists, American College of Endocrinologists, American Association of Endocrine Surgeons (AACE/AAES): Medical/ surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract 2001, 7:202–220.

    Google Scholar 

  19. Pelizzo MR, Bernante P, Toniato A, Piotto A, Gemo G, Pagetta C, Bernardi C: Guidelines for the diagnosis of thyroid carcinoma. J Exp Clin Cancer Res 1997, 16:427–428.

    PubMed  CAS  Google Scholar 

  20. National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology: comprehensive review of thyroid cancer guidelines and literature; 2003.

  21. D’Avanzo A, Ituarte P, Treseler P, Kebebew E, Wu J, Wong M, Duh QY, Siperstein AE, Clark OH: Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 2004, 14:453–8.

    Article  PubMed  CAS  Google Scholar 

  22. Alzahrani AS, Al Mandil M, Chaudhary MA, et al.: Frequency and predictive factors of malignancy in residual thyroid tissue and cervical lymph nodes after partial thyroidectomy for differentiated thyroid cancer. Surgery 2002, 131:443–449. Useful guide to plan of extent of surgery in thyroid cancer patients.

    Article  PubMed  Google Scholar 

  23. Shah JP, Loree TR, Dharker D, Strong EW: Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. Am J Surg 1993, 166:331–335.

    Article  PubMed  CAS  Google Scholar 

  24. Samaan NA, Maheshwari YK, Nader S, et al.: Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983, 56:1131–1138.

    PubMed  CAS  Google Scholar 

  25. Beenken S, Roye D, Weiss H, et al.: Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg 2000, 179:51–56.

    Article  PubMed  CAS  Google Scholar 

  26. Kebebew E, Duh QY, Clark OH: Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World J Surg 2000, 24:1295–1302.

    Article  PubMed  CAS  Google Scholar 

  27. Kupferman ME, Mandel SJ, DiDonato L, et al.: Safety of completion thyroidectomy following unilateral lobectomy for well-differentiated thyroid cancer. Laryngoscope 2002, 112:1209–1212. Discusses safety and morbity assosciated with the surgical procedures for thyroid cancer.

    Article  PubMed  Google Scholar 

  28. Nakano S, Uenosono Y, Ehi K, et al.: Lymph nodes mapping for detection of sentinel nodes in patients with papillary thyroid cancer. Gan To Kagaku Ryoho 2004, 31:801–804.

    PubMed  Google Scholar 

  29. Marchesi M, Biffoni M, Biancari F, Berni A, Campana FP: Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. Eur J Surg Suppl 2003:46–50. Identifies risk factors to guide surgeons on the extent of surgery.

  30. Ducci M, Appetecchia M, Marzetti M: Neck dissection for surgical treatment of lymphnode metastasis in papillary thyroid carcinoma. J Exp Clin Cancer Res 1997, 16:333–335.

    PubMed  CAS  Google Scholar 

  31. Catz B, Petit DW, Schwartz H, et al.: Treatment of cancer of the thyroid postoperatively with suppressive thyroid medication, radioactive iodine, and thyroid-stimulating hormone. Cancer 1959, 12:371–383.

    Article  PubMed  CAS  Google Scholar 

  32. Taylor T, Specker B, Robbins J, et al.: Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998, 129:622–627.

    PubMed  CAS  Google Scholar 

  33. Haugen BR: Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord 2000, 1:139–145.

    Article  PubMed  CAS  Google Scholar 

  34. Baudin E, Schlumberger M, Lumbroso J, et al.: Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996, 81:2541–2544.

    Article  PubMed  CAS  Google Scholar 

  35. Klain M, Ricard M, Leboulleux S, et al.: Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002, 29(Suppl 2):479–485.

    Article  CAS  Google Scholar 

  36. Goldman JM, Line BR, Aamodt RL, Robbins J: Influence of triiodothyronine withdrawal time on 131I uptake post-thyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980, 50:734–739.

    Article  PubMed  CAS  Google Scholar 

  37. Cooper DS, Specker B, Ho M, et al.: Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998, 8:737–744.

    Article  PubMed  CAS  Google Scholar 

  38. Pujol P, Daures JP, Nsakala N, etx al.: Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81:4318–4323.

    Article  PubMed  CAS  Google Scholar 

  39. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B: Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990, 113:265–269.

    PubMed  CAS  Google Scholar 

  40. Biondi B, Palmieri EA, Fazio S, et al.: Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000, 85:4701–4705.

    Article  PubMed  CAS  Google Scholar 

  41. Mazzaferri EL, Young RL: Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981, 70:511–518.

    Article  PubMed  CAS  Google Scholar 

  42. Tsang RW, Brierley JD, Simpson WJ, et al.: The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998, 82:375–388. Retrospective report of the role of EBRT in differentiated thyroid cancer.

    Article  PubMed  CAS  Google Scholar 

  43. Simpson WJ, Panzarella T, Carruthers JS, et al.: Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988, 14:1063–1075. Statistically improved local control demonstrated with EBRT.

    PubMed  CAS  Google Scholar 

  44. Philips P, Hanzen C, Andry G, et al.: Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 1993, 19:399–404.

    Google Scholar 

  45. Ford D, Giridharan S, McConkey C, et al.: External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2003, 15:337–341. Describes dose response to EBRT.

    CAS  Google Scholar 

  46. Ahuja S, Ernst H: Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987, 10:303–310.

    PubMed  CAS  Google Scholar 

  47. Droz JP, Schlumberger M, Rougier P, et al.: Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990, 76:480–483.

    PubMed  CAS  Google Scholar 

  48. Williams SD, Birch R, Einhorn LH: Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986, 70:405–407.

    PubMed  CAS  Google Scholar 

  49. Schmutzler C, Koehrle J: Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol 2000, 143:15–24. Excellent review of emerging novel treatments for thyroid cancer.

    Article  PubMed  CAS  Google Scholar 

  50. Grunwald F, Menzel C, Bender H, et al.: Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998, 39:1903–1906.

    PubMed  CAS  Google Scholar 

  51. Mandell RB, Mandell LZ, Link CJ, Jr: Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999, 59:661–668.

    PubMed  CAS  Google Scholar 

  52. Grigsby PW, Baglan K, Siegel BA: Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 1999, 85:945–951.

    Article  PubMed  CAS  Google Scholar 

  53. Baskin HJ: Thyroid ultrasonography: a review. Endocr Pract 1997, 3:153–157. Highlights use of thyroid ultrasound in diagnosis and follow up of thyroid cancer patients.

    PubMed  CAS  Google Scholar 

  54. Spencer CA, Takeuchi M, Kazarosyan M, et al.: Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998, 83:1121–1127.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernandes, J.K., Day, T.A., Richardson, M.S. et al. Overview of the management of differentiated thyroid cancer. Curr. Treat. Options in Oncol. 6, 47–57 (2005). https://doi.org/10.1007/s11864-005-0012-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0012-3

Keywords

Navigation